CogRX receives $16.6M Grant for Phase II Study of Alzheimer’s Drug

Sofia Fund portfolio company CogRX has received a $16.6M Multi-Year Grant for Phase II studies of its Elayta™ drug for mild-to-moderate Alzheimer’s disease.   Learn more at CogRX announces NIA grant